Fed Governor Adriana Kugler to resign
On Wednesday, Brookline Capital Markets maintained its Buy rating and $198.00 price target for Moderna stock (NASDAQ:MRNA), currently trading at $26.69, following the company’s decision to withdraw and resubmit the Biologics License Application (BLA) for its combination flu/COVID vaccine, mRNA-1083. According to InvestingPro data, the stock has shown significant volatility, trading 84% below its 52-week high of $170.47, though it has recently rebounded with a 16.5% gain over the past week. The firm’s analyst Leah Rush Cann provided insights into the implications of this development for the biotechnology company’s future prospects.
Moderna announced its intention to prioritize the mRNA-1083 vaccine for older adults at higher risk. The initial BLA filing took place in early 2025, and the company did not utilize a priority review voucher. Brookline Capital Markets does not expect the withdrawal and resubmission to impact the projected 2026 launch and adoption of the vaccine. The analyst highlighted that despite the possibility of approval coming as late as late 2025, no revenue from the product was expected before the 2026/2027 flu season. InvestingPro analysis shows the company maintains strong liquidity with a current ratio of 4.22, though it faces near-term challenges with analysts projecting a 35% revenue decline this year.
The firm remains confident in Moderna’s timeline, bolstered by positive data from the phase III pivotal study of mRNA-1083 reported in 2024. The analyst projects that mRNA-1083 could successfully launch in 2026 and potentially generate sales of $2.23 billion by 2030. This would represent over 6% of Moderna’s total product sales in 2030.
The potential benefits of combination vaccines were also noted, with ease-of-use for administration and availability being key advantages. Such vaccines could offer more convenience for patients, which may lead to higher adoption and compliance rates for COVID-19 and influenza vaccinations, particularly in the United States.
In other recent news, Moderna Inc (BMV:MRNA). reported its first-quarter 2025 earnings, revealing a narrower-than-expected loss of $2.52 per share, compared to the anticipated loss of $3.18. The company, however, faced a revenue shortfall with $108 million reported, falling short of the $115.3 million forecast. In a strategic move, Moderna has withdrawn its application for its flu/COVID combination vaccine, mRNA-1083, intending to resubmit it later this year with new data from an ongoing Phase 3 trial. Concurrently, Berenberg maintained its Hold rating on Moderna, highlighting the company’s cost-cutting efforts but noting commercial challenges. The U.S. Food and Drug Administration (FDA) is requiring new clinical trials for annual COVID-19 boosters for healthy individuals under 65, potentially affecting vaccine manufacturers, including Moderna. The Department of Health and Human Services is also expected to change its recommendations for routine COVID-19 vaccines for certain groups, which could impact vaccine producers like Moderna. These developments come as Moderna continues to advance its vaccine and oncology pipelines, with plans for future product launches and regulatory approvals.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.